This endorsement specifically pertains to its primary application as a therapeutic option for individuals diagnosed with metastatic NSCLC featuring EGFR Exon 19 deletion or Exon 21 L858R substitution mutations [40]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.